Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2201
BioCryst Pharmaceuticals
BCRX
$2.45B
| $2.25M | ﹤0.01% |
404,503
+185,300
| +85% | +$1.13M |
|
2202
American Superconductor
AMSC
$1.54B
| $2.25M | ﹤0.01% |
486,188
+26,600
| +6% | +$135K |
|
2203
Wolverine World Wide
WWW
$1.71B
| $2.25M | ﹤0.01% |
+80,200
| New | +$2.03M |
|
2204
NWPX Infrastructure Inc
NWPX
$1.12B
| $2.23M | ﹤0.01% |
137,000
-8,300
| -6% | -$122K |
|
2205
AstroNova
ALOT
$226M
| $2.23M | ﹤0.01% |
172,650
+23,100
| +15% | +$329K |
|
|
SPRT
2206
DELISTED
support.com, Inc.
SPRT
| $2.23M | ﹤0.01% |
955,697
+73,234
| +8% | +$171K |
|
2207
Chicago Rivet & Machine Co
CVR
$9.92M
| $2.22M | ﹤0.01% |
59,500
-600
| -1% | -$23.4K |
|
|
RT
2208
DELISTED
Ruby Tuesday Georgia
RT
| $2.22M | ﹤0.01% |
1,105,569
-425,800
| -28% | -$1.01M |
|
2209
Buckle
BKE
$2.27B
| $2.22M | ﹤0.01% |
124,750
+91,900
| +280% | +$1.64M |
|
|
CCEC
2210
Capital Clean Energy Carriers
CCEC
$1.36B
| $2.21M | ﹤0.01% |
93,087
-66,575
| -42% | -$1.59M |
|
|
PKD
2211
DELISTED
Parker Drilling Company
PKD
| $2.2M | ﹤0.01% |
108,807
+6,207
| +6% | +$140K |
|
|
PFNX
2212
DELISTED
Pfenex Inc.
PFNX
| $2.2M | ﹤0.01% |
549,100
+223,300
| +69% | +$1.03M |
|
|
PFBI
2213
DELISTED
Premier Financial Bancorp
PFBI
| $2.19M | ﹤0.01% |
133,039
+3,501
| +3% | +$57.9K |
|
|
NM
2214
DELISTED
Navios Maritime Holdings Inc.
NM
| $2.19M | ﹤0.01% |
159,880
-32,090
| -17% | -$470K |
|
|
VLRS
2215
Controladora Vuela Compania de Aviacion
VLRS
$900M
| $2.19M | ﹤0.01% |
150,400
-573,700
| -79% | -$7.86M |
|
|
HIL
2216
DELISTED
Hill International, Inc. Common Stock
HIL
| $2.19M | ﹤0.01% |
420,400
-44,000
| -9% | -$200K |
|
2217
Huntington Bancshares
HBAN
$36.1B
| $2.18M | ﹤0.01% |
161,544
-923,300
| -85% | -$11.9M |
|
2218
Trex
TREX
$5.05B
| $2.18M | ﹤0.01% |
128,800
-324,800
| -72% | -$5.48M |
|
|
VBTX
2219
DELISTED
Veritex Holdings
VBTX
| $2.17M | ﹤0.01% |
82,300
-50,600
| -38% | -$1.36M |
|
2220
Northrim BanCorp
NRIM
$604M
| $2.15M | ﹤0.01% |
283,600
-88,400
| -24% | -$678K |
|
2221
uniQure
QURE
$3.28B
| $2.15M | ﹤0.01% |
348,100
-25,900
| -7% | -$140K |
|
|
BBU
2222
DELISTED
Brookfield Business Partners
BBU
| $2.15M | ﹤0.01% |
123,711
+54,246
| +78% | +$912K |
|
2223
Standard BioTools
LAB
$286M
| $2.15M | ﹤0.01% |
531,000
+54,600
| +11% | +$259K |
|
|
RCM
2224
DELISTED
R1 RCM Inc. Common Stock
RCM
| $2.14M | ﹤0.01% |
571,100
+537,100
| +1,580% | +$1.97M |
|
|
HEP
2225
DELISTED
Holly Energy Partners, L.P.
HEP
| $2.14M | ﹤0.01% |
65,900
+15,273
| +30% | +$520K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.